Industry News
Pharmaceutical Industry News
A Powerful H.I.V. Drug Lands in Zambia. But Will It Reach Those Who Need It?
Lenacapavir, which protects people from H.I.V. infection with twice-yearly shots, is arriving in a country where the health system has been hollowed out by American aid cuts.
Eli Lilly to Buy 3 Vaccine Developers
The drugmaker said it would spend up to $4 billion to acquire small companies exploring vaccines for shingles, Epstein-Barr virus and other pathogens.
The potential $7 billion buyout…
The potential $7 billion buyout deal in the radiopharmaceutical space could be weeks away, Bloomberg reported, citing people familiar with the matter.
Korea’s SK bioscience has signed…
Korea’s SK bioscience has signed a technology transfer and manufacturing deal with the Colombian government which will allow the South American nation to produce the company’s chickenpox vaccine SKYVaricella.
More than three years after Gilead…
More than three years after Gilead Sciences’ hepatitis D drug bulevirtide was rebuffed by the FDA on manufacturing and delivery concerns, the treatment has redeemed itself by scoring a green light in the U.S.
Inside the Evolution of Synthetic Drugs
Natalie Kitroeff from “The Daily” speaks with Azam Ahmed, a New York Times international investigative correspondent, about his latest piece on the synthetic drug crisis.
Two years after launching its…
Two years after launching its “More To Parkinson’s” campaign with actor Ryan Reynolds, Acadia Pharmaceuticals is asking Reynolds to suit up once again as it broadens the project.
Niowave has broken ground on a $75…
Niowave has broken ground on a $75 million facility at its campus in Lansing, Michigan, which will produce Actinium-225. The radioisotope supplier expects the facility to become operational in 2028 and to employ 70 people.
The layoffs at AbbVie’s Irvine,…
The layoffs at AbbVie's Irvine, California, location will take effect on July 20, according to a recent WARN notice.
Less than a month after an FDA…
Less than a month after an FDA advisory committee recommended rejection of AstraZeneca’s novel cancer drug, Europe’s CHMP has blessed Etcamah with a positive opinion. The EMA also has signed off on Novo Nordisk's Wegovy
AbbVie’s 85 layoffs are tied to…
AbbVie's 85 layoffs are tied to its Allergan Aesthetics headquarters in California, while Novartis is cutting more staff at its U.S. HQ in New Jersey.
A three-way battle among TROP2…
A three-way battle among TROP2 ADCs in first-line triple-negative breast cancer is forming as AstraZeneca and Daiichi Sankyo's Datroway became the first to cross the FDA's finish line.
AbbVie and GSK have surged up the…
AbbVie and GSK have surged up the rankings of the pharma companies with the best reputations among U.K. patient groups, contributing to turnover at the top of the leaderboards.
Merck & Co. and…
Merck & Co. and Kelun-Biotech's sac-TMT is on fire this week with reports of three positive phase 3 trials. Local know-how, proper due diligence and AI are helpful in striking licensing deals in China, experts
Tyra Biosciences has partnered…
Tyra Biosciences has partnered with a patient advocacy group to create an awareness day for upper tract urothelial cancer, a rare tumor type its lead drug candidate targets.
A web of mail-order pharmacies,…
A web of mail-order pharmacies, wholesalers and patient services groups connected to the self-styled largest Pentecostal denomination in the U.S. has been accused of defrauding pharma juggernaut Eli Lilly out of more than $200 million
According to an abstract released…
According to an abstract released ahead of the ASCO 2026 annual meeting, combining the TROP2-directed ADC with Keytruda slashed the risk of disease progression or death by a whopping 65% compared with Keytruda alone in
After the drug’s local license…
After the drug’s local license holder called for a brief pause in new patient starts last week, doctors in Japan can once again prescribe Amgen’s rare autoimmune disease med Tavneos (avacopan), albeit with revised safety
Gilead’s five-year contract with…
Gilead’s five-year contract with the WHO is centered on providing AmBisome to countries that make up 74% of the global visceral leishmaniasis burden, according to the company.
Experimental Drug Yields Dramatic Weight Loss
People who got the injection, retatrutide, lost 28 percent of their body weight on average after 80 weeks, Eli Lilly said.